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RESEARCH ARTICLE
Mammalian copper homeostasis requires retromer-dependent
recycling of the high-affinity copper transporter 1
Rachel Curnock* and Peter J. Cullen*
ABSTRACT
The concentration of essential micronutrients, such as copper (used
here to describe both Cu+ and Cu2+), within the cell is tightly regulated
to avoid their adverse deficiency and toxicity effects. Retromer-
mediated sorting and recycling of nutrient transporters within the
endo-lysosomal network is an essential process in regulating nutrient
balance. Cellular copper homeostasis is regulated primarily by two
transporters: the copper influx transporter copper transporter 1 (CTR1;
also known as SLC31A1), which controls the uptake of copper, and the
copper-extruding ATPase ATP7A, a recognised retromer cargo. Here,
we show that in response to fluctuating extracellular copper, retromer
controls the delivery of CTR1 to the cell surface. Following copper
exposure, CTR1 is endocytosed to prevent excessive copper uptake.
We reveal that internalised CTR1 localises on retromer-positive
endosomes and, in response to decreased extracellular copper,
retromer controls the recycling of CTR1 back to the cell surface to
maintain copper homeostasis. In addition to copper, CTR1 plays a
central role in the trafficking of platinum. The efficacy of platinum-based
cancer drugs has been correlated with CTR1 expression. Consistent
with this, we demonstrate that retromer-deficient cells show reduced
sensitivity to the platinum-based drug cisplatin.
KEY WORDS: CTR1, Endosomal recycling, Metal ion homeostasis,
Retromer
INTRODUCTION
Integral membrane proteins are delivered and removed from the cell
surface by means of membrane trafficking pathways (Cullen and
Steinberg, 2018). The balance between delivery and internalisation
defines the steady-state cell surface abundance of these proteins and
provides the means to rapidly alter the abundance of individual
proteins and larger groups of functionally related proteins in
response to environmental cues. For responses triggered by, for
example, metabolic cues and toxic stresses, the endocytic network
plays an important role in the adaptive response (Corvera et al.,
1986; Jenness and Spatrick, 1986; Jones et al., 2012; Mueller et al.,
2015; Tanner and Lienhard, 1987). Comprising a number of
intracellular membrane bound compartments, this network sorts
internalised cell surface integral membrane proteins between two
fates – either degradation within the lysosome or retrieval from this
fate for subsequent recycling and reuse at the cell surface (Burd and
Cullen, 2014; Cullen and Steinberg, 2018). By deciding the fate of
proteins that include signalling receptors, nutrient and solute
transporters, cell–cell and cell–matrix adhesion molecules, the
endocytic network can alter the functionality of the cell surface
during a range of extracellular stimuli. However, our understanding of
the role of the endocytic retrieval and recycling pathways in adaptive
responses has been hampered by a lack of basic understanding of the
machinery that regulates these pathways (Bai et al., 2012; Grant and
Donaldson, 2009; McNally and Cullen, 2018).
Several protein complexes have now been identified that control
the sorting of internalised integral proteins for retrieval and
recycling (Arighi et al., 2004; Derivery et al., 2009; Gomez and
Billadeau, 2009; McNally et al., 2017; Phillips-Krawczak et al.,
2015; Seaman, 2004; Seaman et al., 1998; Simonetti et al., 2019).
These include the mammalian retromer, a stable heterotrimeric
complex of VPS35, VPS29 and VPS26 of which two isoforms,
VPS26A and VPS26B, are expressed in humans (Arighi et al.,
2004; Kerr et al., 2005; Seaman, 2004; Seaman et al., 1998).
Retromer functions by scaffolding an endosome-associated multi-
protein assembly that co-ordinates sequence-dependent cargo
selection with the biogenesis of cargo-enriched transport carriers
that deliver the sorted cargo back to the cell surface (Burd and
Cullen, 2014; Wang et al., 2018). Important retromer accessory
proteins include the cargo adaptor sorting nexin-27 (SNX27) and
the actin polymerising FAM21-containing Wiskott–Aldrich
syndrome protein and Scar homology (WASH) complex (Gallon
et al., 2014; Gomez and Billadeau, 2009; Harbour et al., 2012; Jia
et al., 2012; Steinberg et al., 2013; Temkin et al., 2011). Retromer
regulates the endosomal retrieval and recycling of numerous
integral membrane proteins that include a number of transporters
for the uptake and extrusion of essential but also toxic transition
metals, such as copper (used here to describe both forms of Cu
found in the body – Cu+ and Cu2+; Steinberg et al., 2013). It is clear
retromer is central to regulating cargo traffic through the endosomal
network and we recently recognised that retromer itself is tightly
regulated in response to extracellular cues (Curnock et al., 2019).
Many retromer-dependent cargoes have been identified (Cullen
and Steinberg, 2018). The copper-transporting ATPase ATP7A is an
established retromer cargo, and its expression at the cell surface upon
copper elevation requires retromer and SNX27 (Steinberg et al.,
2013). Cellular copper homeostasis is regulated by two principal
transporters: the copper pumping ATP7A and ATP7B, which
sequesters copper into the trans-Golgi-network (TGN) and
mobilises copper to the cell periphery, and the structurally
unrelated cell surface localised copper transporter 1 (CTR1; also
known as SLC31A1) which controls the uptake of copper from the
extracellular environment (Hartwig et al., 2019; Hung et al., 1997;
Lee et al., 2002; Petris et al., 1996). Cellular adaptation to elevated
extracellular copper is mediated by membrane trafficking pathways
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that deliver ATP7A to the cell surface to enhance the extrusion of
copper, and the endocytosis of CTR1, which serves to prevent further
copper uptake and accumulation (Kim et al., 2008). Copper is an
essential micronutrient, vital for development and growth but in
excess it is toxic (Madsen and Gitlin, 2007). Understandably,
homeostatic copper uptake and distribution is tightly controlled. The
adverse effects of copper misbalance manifest in the neurological
disorders Menkes and Wilson’s diseases, resulting from copper
deficiency and overload, respectively (Daniel et al., 2004). Abnormal
copper accumulation has also been linked with neuronal cell death
and disease pathology in neurodegenerative disorders such as
Parkinson’s disease (PD) (Madsen and Gitlin, 2007). It is now
well-established that mutations leading to perturbed retromer function
are risk factors for the development of PD (McMillan et al., 2017). In
addition to the established role for retromer in ATP7A transport, we
previously identified the main copper uptake transporter CTR1 as a
putative retromer cargo (Steinberg et al., 2013). Therefore, to fully
appreciate whether there is a link between retromer function, copper
homeostasis and potentially PD progression, in this study we
examined the membrane trafficking of CTR1.
The high-affinity copper transporter CTR1 is evolutionarily
conserved, mediating the cellular import of copper in eukaryotes
from fungi to vertebrates, and is the only known mammalian importer
of copper (Dancis et al., 1994; Zhou and Gitschier, 1997). CTR1
exists in the plasma membrane as a homo-trimer with an extracellular
N-terminal region, three transmembrane helices and an intracellular
C-terminus (Eisses and Kaplan, 2005; Klomp et al., 2002; Lee et al.,
2002; Puig et al., 2002; Ren et al., 2019). Deletion studies in mice
have demonstrated that CTR1 is essential for development with
early embryonic lethality in homozygous knockout animals (Kuo
et al., 2001; Lee et al., 2001). Characterisation of heterozygote mice
has revealed that they have a severe deficiency in brain copper
concentration, indicating a crucial role for CTR1 in copper uptake and
distribution in the brain (Kuo et al., 2001; Lee et al., 2001). In addition
to the cellular import of copper, CTR1 has also been implicated in the
cellular uptake and accumulation of platinum-derived anticancer
drugs, such as cisplatin, carboplatin and oxaliplatin (Holzer et al.,
2006). Furthermore, responsiveness to these platinum-based
chemotherapeutic agents in cancer patients has been correlated with
high levels of CTR1 expression (Song et al., 2004). The occupancy
and turnover ofCTR1 at the plasmamembrane is therefore pertinent to
not only cellular copper homeostasis but also the efficacy of platinum-
based cancer drugs. In the present study, using RNAi-mediated
suppression and CRISPR-Cas9-mediated knockout of VPS35, we
have investigated whether the cell surface levels and trafficking of
CTR1 in response to changes in extracellular copper concentration are
dependent on retromer expression. We find, by performing antibody
internalisation studies in the presence of copper and confocal analysis,
that internalised CTR1 resides on retromer-positive endosomes. Cell
surface biotinylation experiments togetherwith flow cytometry revealed
that CTR1 basal cell surface levels and copper concentration-dependent
delivery to the cell surface relies on retromer expression. The effects of
increasing extracellular copper and exposure to cisplatin, the most
commonly used platinumchemotherapy drug, onmetabolic activity and
cell viability were assessed using colorimetric MTT assays. We
demonstrate that retromer is essential for full sensitivity to
extracellular copper loading and cisplatin toxicity.
RESULTS
Retromer is required for the cell surface localization of CTR1
A multitude of metal ion transporters were previously identified as
SNX27 and/or retromer cargo using a global unbiased approach
(Steinberg et al., 2013). The cell surface levels of a distinct subset of
transporters were not reliant on the expression of the accessory
protein SNX27 and were found to be solely retromer dependent.
The main mammalian copper importer, CTR1, was one such
transporter (Steinberg et al., 2013). To validate this finding, SNX27
and the core component of the retromer complex VPS35 were
efficiently suppressed using siRNA (denoted as siSNX27 and
siVPS35, respectively) and cell surface biotinylation followed by
fluorescence-based quantitative western blotting was used to assess
the cell surface abundance of CTR1. A significant reduction in the
cell surface levels of CTR1 was observed in cells suppressed for
VPS35 but not SNX27 (Fig. 1A). Notably, as would be anticipated,
the cell surface levels of ATP7A, an established retromer and
SNX27 cargo (Steinberg et al., 2013) were depleted in cells treated
with siRNA targeting VPS35 and SNX27 (Fig. 1A).
Immunofluorescence analysis revealed a reduction in CTR1
signal intensity at the cell surface in VPS35 suppressed cells
(Fig. 1B). Furthermore, flow cytometry in VPS35-knockout (KO)
HeLa cells confirmed a significant reduction in the abundance of
cell surface CTR1 in the absence of retromer function (Fig. 1C).
In response to elevated extracellular copper, CTR1 is internalised
in a dynamin- and clathrin-dependent manner to prevent excess
copper uptake (Clifford et al., 2016). To visualise the trafficking of
CTR1, we performed antibody internalisation in the presence of
copper (200 µM CuCl2). Here, cells on ice were surface labelled
with an antibody against an exofacial epitope of CTR1 and then
allowed to internalise the antibody bound CTR1 during an
incubation at 37°C in growth medium supplemented with 200 µM
CuCl2. Cells were subsequently fixed prior to immunofluorescence
and colocalization analysis using LAMP1 as a marker of the
degradative lysosomal compartment. After 2 h in the presence of
copper, a significant increase in colocalization between CTR1 and
LAMP1 was observed in HeLa cells treated with siRNA targeting
VPS35 (Fig. 2A) and in VPS35 KO HeLa cells (Fig. 2B). Under
these conditions, in control cells and following RNAi-mediated
suppression or CRISPR-Cas9-mediated knockout of SNX27, CTR1
localised to the cell peripherally or LAMP1-negative intracellular
compartments. SNX27 does not therefore make a significant
contribution to the copper-dependent sorting of CTR1.
To ensure that the observed mis-sorting and reduction of
CTR1 from the cell surface was specific to loss of retromer, we
re-expressed VPS35 in VPS35 KO cells and examined the surface
levels of CTR1 using flow cytometry. Upon re-expression of
VPS35, the cell surface levels of CTR1 were restored to control
levels (Fig. 3A). This recovery of CTR1 levels at the cell surface
following re-expression of VPS35 was also observed through
surface biotinylation experiments (Fig. 3B). Taken together, these
data demonstrate that internalised CTR1 is retrieved from entering
lysosomes and promoted for recycling back to the cell surface
through a retromer-dependent pathway. Retromer is therefore
required for controlling the cell surface residency of CTR1.
Internalized CTR1 resides on retromer-positive endosomes
Following a 30 min exposure to extracellular copper, internalised
CTR1 has been reported to localise to EEA1- and transferrin
receptor-positive early endosomes (Clifford et al., 2016). Therefore,
we next sought to visualise whether, following its copper-induced
internalisation, CTR1 traffics via a retromer-positive endosomal
route. Cells were surface labelled on ice with an endogenous
antibody to CTR1 and subsequently incubated at 37°C in excess
copper-containing medium (200 µM CuCl2) or standard growth
medium for 30 min prior to immunofluorescence processing. Cells
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were co-labelled with antibodies against endogenous CTR1 (red)
and VPS35 (green). As anticipated, in cells maintained in standard
low-copper growth medium, CTR1 remained at the cell surface. By
contrast, in cells where CTR1 had undergone copper-induced
internalisation we found that CTR1 extensively localised to VPS35-
positive endosomes. Quantification of the Pearson’s correlation
revealed that there was a significant increase in the colocalization
between CTR1 and VPS35 in cells exposed to copper (Fig. 4A).
To determine whether the above pathway reflects a ubiquitous
trafficking route for CTR1, we performed the CTR1 copper-induced
internalisation assay in two different cell lines, H1299 and H1975
cells, both of which are human non-small-cell lung cancer (NSCLC)
cell lines. Notably, CTR1 was readily internalised in response to
elevated copper in both these cell lines. As observed in HeLa cells
(Fig. 4A), in copper-treated H1299 and H1975 cells, internalised
CTR1 localised to VPS35-positive endosomes and this correlated
with a significant increase in the Pearson’s correlation between
CTR1 and VPS35 (Fig. 4B,C). Together, these data provide further
supporting evidence that, in response to elevated extracellular
copper, internalised CTR1 is transported through retromer-positive
endosomes.
Retromer-dependent CTR1 trafficking is vital for copper
homeostasis
Cellular adaptation to the ever-changing extracellular environment
is fundamental to cell homeostasis and survival. Through regulating
the constant flux of transmembrane proteins, the endosomal
network is fundamental to the remodelling of the cell surface in
response to extracellular cues (Curnock et al., 2019). To examine the
importance of retromer-dependent CTR1 trafficking for copper
homeostasis, we established a protocol to periodically incubate cells
for 1 h in high copper containing medium (200 μMCuCl2) followed
by a 1 h incubation in normal growth medium to effect a copper
washout (Fig. 5). This revealed a tight reciprocal coupling between
CTR1 expression at the cell surface and the presence of elevated
copper (Fig. 5). Thus, upon addition of high concentrations of
copper, CTR1 underwent endocytosis and then recycling back to
the cell surface following copper washout. Entirely consistent with
retromer regulating the recycling of internalised CTR1, the ability of
cells to adapt to periodic exposure to elevated copper was
completely lost upon retromer depletion (Fig. 5).
To appreciate the role of retromer-dependent CTR1 trafficking
in copper homeostasis, we next performed MTT assays to assess
Fig. 1. Retromer maintains the cell surface abundance of the evolutionarily conserved copper importer, CTR1. (A) HeLa cells were treated with non-
targeting (control) siRNA or siRNA targeting VPS35 (siVPS35) or SNX27 (siSNX27) for 72 h. Cells were then surface biotinylated and streptavidin–agarose
used to capture biotinylated membrane proteins. Surface abundance of the indicated proteins were assessed by immunoblotting. Data were normalized to
levels of N-cadherin. (B) HeLa cells were treated with non-target control siRNA or siRNA targeting VPS35 for 72 h. Cells were then immunostained for cell surface
CTR1 (red). The pseudocoloured panel represents the CTR1 signal intensity. Scale bars: 40 μm. (C) Quantitative analysis by flow cytometry of surface CTR1
levels in control and VPS35 KO HeLa cells. Bars represent the change in CTR1 cell surface levels in VPS35 KO cells versus control cells. Data in A and C
represent mean±s.e.m.; n=3 independent experiments. *P<0.05; **P<0.01 (unpaired Student’s t-test).
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the effect of increasing extracellular copper on metabolic activity,
as an indicator of cell viability. This colorimetric assay measures
the ability of NAD(P)H-dependent oxidoreductases and
dehydrogenases localized to cytoplasm and mitochondria to
reduce MTT, a water-soluble tetrazolium dye, to a purple,
insoluble formazan (Berridge et al., 2005). Control and VPS35
KO HeLa cells were subjected to nine extracellular copper (CuCl2)
concentrations from 3.125 µM to 800 µM for 48 or 72 h, and MTT
reduction was measured by determining the absorbance at 595 nm.
In control cells after exposure to 400 µM copper for 48 h, a
dramatic decline in metabolised MTT, correlating with a decrease
in cell viability was observed (Fig. 6A). Strikingly, compared to
control cells, VPS35 KO cells showed significantly reduced
sensitivity to higher concentrations of extracellular copper. After
48 h exposure to 400 µM copper, VPS35 KO cells still maintained
the ability to metabolise MTT (Fig. 6A). With prolonged exposure
to copper for 72 h, this difference in copper sensitivity between
control and VPS35 KO cells became more pronounced (Fig. 6B).
After 72 h, the toxic effects of the copper exposure were observed
at lower concentrations in control cells; however, this was not as
evident in VPS35 KO cells (Fig. 6B). Importantly, we found that
sensitivity to copper was restored upon re-expression of VPS35,
thus demonstrating that the ability of the cell to sense and
respond to toxic levels of extracellular copper relies on retromer
function (Fig. 6C).
Retromer expression is required for maximal cisplatin
toxicity
In addition to its role as the main transporter responsible for the
cellular influx of copper, CTR1 has also been linked to the
intracellular accumulation of platinum and therefore also platinum-
containing cancer drugs (Howell et al., 2010). The efficiency of
anti-tumour platinum-based drugs is directly related to the
concentration of the drug that enters the cell. Although the
mechanism is poorly defined and under debate, there is evidence
that CTR1-dependent uptake controls the cytotoxicity of the widely
used chemotherapeutic drugs cisplatin, carboplatin and oxaliplatin
(Bompiani et al., 2016; Holzer et al., 2006; Ivy and Kaplan, 2013).
Studies examining ovarian cancer cell lines and NSCLC patients
samples identified that changes in CTR1 expression were linked to
acquired cisplatin resistance and poor clinical outcome, and
knockout of CTR1 in a murine model has been shown to
eliminate the responsiveness of tumours to cisplatin (Holzer et al.,
2004; Jandial et al., 2009; Kim et al., 2014; Larson et al., 2009).
We have demonstrated above that CTR1 surface abundance relies
on retromer expression and knockout of VPS35 leads to a reduction
in cellular sensitivity to extracellular copper. Therefore, given the
evidence suggesting a dependency on CTR1 for cisplatin uptake and
sensitivity, we next examined whether perturbation of retromer
function affected cell viability in response to cisplatin exposure. We
incubated control and VPS35 KO HeLa cells with nine increasing
Fig. 2. CTR1 is reduced from the cell surface and
mis-sorted into lysosomes in the absence of
VPS35, but not SNX27. (A,B) Antibody uptake with
an antibody against endogenous CTR1.
Immunofluorescence staining and colocalization
analysis following a 2 h incubation in CuCl2
(200 µM) at 37°C. Internalised CTR1 (green) and
lysosomal marker LAMP1 (red) in control, and (A)
VPS35 and SNX27 siRNA and (B) CRISPR-Cas9
knockout HeLa cells. The graphs represent means
±s.e.m.; n=3 independent experiments with >100
cells per condition. ***P<0.001 (one-way ANOVA
followed by Dunnett’s multiple comparison). Scale
bars: 20 μm (main images); 10 μm (zoom panels).
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concentrations of cisplatin (from 0.39 μM to 100 μM). After 48 h, a
significant disparity in the sensitivity of control and VPS35 KO
cells to cisplatin concentrations above 25 μM was observed
(Fig. 7A). These MTT assays revealed that, in the absence of
retromer, HeLa cells were partially desensitised to the toxic effects
of cisplatin. To exclude that this effect was unique to HeLa cells, we
also examined the human NSCLC cell line H1975. We reasoned
that this was a suitable cell line to test this hypothesis, as platinum-
based chemotherapy drugs such as cisplatin and carboplatin form
part of standard therapies commonly used to treat NSCLC (Cosaert
and Quoix, 2002). Furthermore, our immunofluorescence analysis
demonstrated that internalised CTR1 localised to VPS35-positive
endosomes (Fig. 4C) indicating that CTR1 undergoes an endosomal
trafficking route in these cells.
To first validate that retromer is required for CTR1 cell surface
residency in this NSCLC cell line, surface biotinylation was
performed following population-based CRISPR-Cas9-mediated
knockout of VPS35. Consistent with the results in HeLa cells
(Figs 1A and 3B), a significant reduction in the cell surface levels of
CTR1 was observed in VPS35-depleted H1975 cells (Fig. 7B).
Notably, a loss of the copper-transporting ATPase ATP7A was also
detected, indicating that analogous to the situation in HeLa cells, in
H1975 cells both the major cellular copper transporters responsible
for maintaining copper homeostasis are affected by loss of retromer
function. We next assessed, using MTT assays whether perturbed
retromer function effected sensitivity to cisplatin as observed in HeLa
cells (Fig. 5A). Following 48 h in the presence of cisplatin, VPS35-
depleted H1975 cells displayed a trend towards reduced sensitivity to
cisplatin compared to that in the control counterparts (Fig. 7C).
Across different cell lines retromer is therefore required for cisplatin
toxicity, implying that disruption of retromer function might lead to a
reduction in efficacy of platinum-based cancer drugs.
DISCUSSION
Regulated copper homeostasis is fundamental in mammalian cells.
Copper is an essential substrate for cell growth and differentiation, a
cofactor of many enzymes and has even recently been identified as
being necessary for ULK1 and ULK2 signalling, linking it to
autophagy activity (Kim et al., 2008; Tsang et al., 2020). Therefore,
it is unsurprising there are severe adverse effects associated with
copper dyshomeostasis. Treatment for diseases resulting in acute
cellular copper imbalances, such as Menkes disease, are limited and
prognosis is poor (de Bie et al., 2007). As the only known
mammalian importer of copper, CTR1 could be a prospective
pharmacological target. Therefore, gaining better insight into the
membrane trafficking of CTR1 will enhance our mechanistic
understanding of the regulation of cellular copper import and
distribution, leading to a better appreciation for how this may be
manipulated in disease.
The endosomal system is fundamental to organising the spatial
distribution of integral membrane proteins, such as metal
transporters (Cullen and Steinberg, 2018). In response to elevated
extracellular copper, ATP7A traffics from the TGN to the cell
surface where it extrudes excess copper out of the cell (Petris et al.,
1996; Polishchuk and Lutsenko, 2013). Maintaining the cell surface
level of ATP7A under basal conditions and following copper
elevation is reliant upon retromer and SNX27 orchestrating the
endosomal retrieval and recycling of the internalised pump
(Clairfeuille et al., 2016; Steinberg et al., 2013). This acute
regulatory trafficking response requires a direct interaction between
the PDZ-binding motif present in the C-terminal tail region of
ATP7A and the PDZ-domain-containing SNX27 to mediate the
endosomal delivery of ATP7A to the cell surface (Steinberg et al.,
2013). In the present work, we demonstrate that CTR1 is an
additional retromer cargo and that retromer is required for the cell to
Fig. 3. Re-expression of VPS35 rescues cell
surface levels of CTR1. (A) Cell surface CTR1
levels were analysed by flow cytometry in
control and VPS35 KO HeLa cells transduced
with GFP control or GFP–VPS35 as indicated.
Quantification represents the change in CTR1
cell surface levels relative to the control cells
expressing GFP. The graphs represent means
±s.e.m.; n=3 independent experiments.
*P<0.05; ns, not significant (one-way ANOVA
followed by Dunnett’s multiple comparison).
(B) Rescue of CTR1 cell surface levels
assessed by surface biotinylation. The
indicated HeLa cells were surface biotinylated
and streptavidin–agarose used to capture
biotinylated membrane proteins. Surface
abundance of the indicated proteins were
examined by immunoblotting.
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adapt to changes in extracellular copper concentration. In response
to elevated extracellular copper, clathrin-dependent endocytosis of
CTR1 is triggered; this serves to lower the CTR1 levels at the
plasma membrane and restrict copper entry (Molloy and Kaplan,
2009). This cellular adaptation is vital to protect the cell from
excessive copper accumulation. Here, we demonstrate that retromer
is required to facilitate the recycling of CTR1 back to the cell surface
when extracellular copper levels are reduced (Fig. 5). This acute
recovery of CTR1 plasma membrane levels suggests that, in the
presence of excess extracellular copper, the internal pool of CTR1 is
not readily degraded and remains endosomally associated and
accessible for retromer-mediated recycling (Fig. 4A–C; Fig. 8). We
were unable to biochemically detect a direct interaction between
CTR1 and retromer or retromer-associated adaptors (data not
shown). We speculate therefore that interactions between CTR1 and
retromer or retromer-associated endosomal recycling machinery are
Fig. 4. Following copper-induced internalization CTR1
colocalizes with retromer. (A–C) Antibody uptake
experiments with an antibody against endogenous CTR1 in
HeLa (A), H1299 (B) or H1975 cells (C). After 30 min incubation
at 37°C in copper-containing medium (200 µM CuCl2)
internalised CTR1 (red) colocalized with endogenous VPS35
(green) on vesicular structures. In cells incubated in control
medium, CTR1 remained extensively at the cell surface. Bars
represent mean±s.e.m. from three independent experiments.
*P<0.05; **P<0.01; ****P<0.0001 (unpaired Student’s t-test).
Scale bars: 20 μm (main images); 10 μm (zoom panels).
Fig. 5. Retromer recycles CTR1 back to the
cell surface in response to a reduction in
extracellular copper concentration. CTR1
surface levels were analysed under copper-
induced (200μM CuCl2 for 1 h) or copper
washout (recovery in control medium for 1 h)
conditions in control and VPS35-depleted cells.
At the indicated time points cells were surface
biotinylated and streptavidin–agarose used to
capture biotinylated membrane proteins. The
surface abundance of CTR1 and the loading
control N-cadherin were examined by
immunoblotting. The graph represents the
means±s.e.m.; n=3 independent experiments.
**P<0.01 (unpaired Student’s t-test).
6
RESEARCH ARTICLE Journal of Cell Science (2020) 133, jcs249201. doi:10.1242/jcs.249201
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
likely to be very transient and possibly even copper dependent. It is
interesting to postulate a system where copper modulates the
conformation of CTR1, or even possibly key recycling machinery
proteins, to regulate their binding and dissociation, thereby coupling
CTR1 recycling to extracellular copper levels.
Following the import of copper by CTR1, copper is transferred to
the cytoplasmic copper chaperone ATOX1 (Kahra et al., 2016).
CTR1 has a short 13-residue cytoplasmic C-terminal tail containing
a highly conserved copper-binding HCH motif that is necessary for
relaying copper to the ATOX1 for delivery to copper-dependent
enzymes (Kahra et al., 2016). NMR spectroscopy performed by
Kahra et al., demonstrated that ATOX1 and the CTR1 tail peptide
containing the HCH motif do not interact in the absence of copper,
but copper exchange readily occurs from the copper-loaded tail
peptide to ATOX1. Copper transfer to high-affinity chaperones is
therefore tightly controlled (Kahra et al., 2016).
For delivery of copper to the secretory pathway, the cytoplasmic
copper chaperone ATOX1 also interacts with the ATPases ATP7A
andATP7B in a copper-dependent manner (Hamza et al., 1999; Larin
et al., 1999; Pufahl et al., 1997). The copper ATPases are known to
form other copper-dependent protein interactions, such as with the
antioxidant enzyme glutaredoxin 1 and the dynactin subunit p62 (also
known as DCTN4) (Lim et al., 2006a,b). Phosphorylation of
the ATPases has also been identified to provide another level of
regulation within the copper transport system with evidence
of copper-stimulated phosphorylation and hyperphosphorylation
(Vanderwerf et al., 2001; Voskoboinik et al., 2003). Understanding
the determinants that regulate copper-induced trafficking for CTR1
and the ATPases could provide fundamental information on how to
modulate this pathway in disease.
It is established that highly conserved methionine residues within
the import pore formed by the CTR1 trimer are essential for copper
binding and uptake activity (Eisses and Kaplan, 2005; Puig et al.,
2002; Ren et al., 2019). Interestingly, the pore diameter does not
permit permeation of larger cisplatin molecules (Ren et al., 2019).
Cisplatin has been proposed to bind to an extracellular proportion of
CTR1 and, distinct from copper, enter the cell via endocytosis
(Larson et al., 2010). Despite their differences in entry mechanism,
the density of CTR1 at the cell surface is pertinent to the amount of
both copper and cisplatin capable of entering the cell.
Indeed, consistent with a reduction in CTR1 at the cell surface
correlating with lower copper and cisplatin uptake, retromer-
deficient cells were significantly less sensitive to copper loading
and cisplatin exposure (Figs 6A–C, 7A,C). These findings suggest a
link between retromer-dependent CTR1 recycling and sensitivity to
these exogenous cellular stressors. Cisplatin resistance has been
linked to CTR1 degradation and knockout in cells and in vivo
(Holzer et al., 2006; Larson et al., 2009). Furthermore, resistance to
platinum-based cancer drugs is a significant obstacle in the
effectiveness of therapy. Low expression of CTR1 has been
associated with poor clinical outcome in NSCLC patients who
had received platinum-based chemotherapy (Kim et al., 2014).
Interestingly, the copper transporting ATPases ATP7A and ATP7B
have been suggested to chelate and/or promote the cellular efflux of
platinum-based drugs (Dolgova et al., 2009; Gupta and Lutsenko,
2009; Katano et al., 2004; Polishchuk and Polishchuk, 2016; Safaei
and Howell, 2005). Studies have revealed a correlation between
elevated ATP7B expression and reduced effectiveness of cisplatin
chemotherapy in cancer patients (Miyashita et al., 2003; Nakayama
et al., 2004). Consequently, targeted downregulation of ATP7B
expression and trafficking is currently being explored as a potential
strategy to increase the efficacy of cisplatin therapy (Mangala et al.,
2009; Mariniello et al., 2020).
Overall, through a variety of approaches, we have shown that
retromer is required for the cell surface localisation and copper-
dependent recycling of CTR1 (Figs 1A,C and 3A,B and 7B). We
propose a working model where upon copper- or cisplatin-
dependent internalisation CTR1 enters retromer-positive
endosomes. Here CTR1 can undergo one of two fates – in
sustained elevated copper, CTR1 remains associated with the
maturing endosome and is degraded within the lysosome (Guo
et al., 2004; Liu et al., 2007; Petris et al., 2003) or, as we
demonstrate in the present work, following a reduction in
Fig. 6. Retromer-dependent cargo recycling is necessary for copper
homeostasis. (A,B) Control and VPS35 KO HeLa cells were incubated with
nine concentrations of CuCl2 ranging from 3.12 to 800 µM for (A) 48 or (B) 72 h.
Each concentration was performed in quadruplicate. MTT reduction was
measured by absorbance at 595 nm. Each data point represents the mean±
s.e.m. absorbance at 595 nm normalised to the baseline reading without
addition of CuCl2; n=4 independent experiments. (C) MTT assays were
performed as described above subjecting VPS35 KO HeLa cells expressing
GFP or GFP–VPS35 to increasing concentrations of CuCl2 for 48 h. Each data
point represents the mean±s.e.m. absorbance at 595 nm normalised to the
baseline reading without addition of CuCl2; n=3 independent experiments.
*P<0.05; **P<0.01; ***P<0.001 (unpaired Student’s t-test).
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extracellular copper levels, CTR1 becomes available for retromer-
dependent recycling back to the cell surface (Fig. 8). Exploring this
model further will reveal greater insight into the regulation and
trafficking of CTR1, and may suggest approaches to manipulate
cellular copper import and distribution in disease and modulating
cellular sensitivity and toxicity to platinum-based treatments.
MATERIALS AND METHODS
Antibodies
Antibodies used in the study were (WB, western blot; IF,
immunofluorescence; FC, flow cytometry): mouse monoclonal antibodies
raised against SNX27 antibody (clone 1C6, Abcam, Ab77799, WB, 1:500,
RRDI AB_10673818), GFP (clones 7.1/13.1, Roche, 11814460001, WB,
1:2000, RRDI AB_390913), LAMP1 (clone H4A3, Developmental Studies
Hybridoma Bank, IF, 1:400, RRDI AB_528126), N-cadherin (clone 32, BD
Biosciences, 610920, WB, 1:1000, RRDI AB_2077527), ATP7A
(clone D9, Santa Cruz Biotechnology sc-376467, WB, 1:1000, RRDI
AB_11150485), transferrin receptor (clone H68.4, Invitrogen 13-6890,
WB, 1:1000, RRDI AB_2533030), β-actin (Sigma-Aldrich, A1978, WB,
1:5000, RRDI AB_476692); rabbit monoclonal antibodies raised
against VPS35 (Abcam, ab157220, WB, 1:2000, RRDI AB_2636885),
SLC31A1/CTR1 (Abcam, ab129067 WB/IF/FC, 1:1000, 1:100, 1:10,
RRDI AB_11150613); rabbit polyclonal antibodies raised against VPS35
(Abcam 97545, IF, 1:200, RRDI AB_10696107) and Isotype Ctrl (clone
Poly29108, Biolegend 910801, FC, 1:10, RRDI AB_2722735). For
Odyssey detection of western blots, thegoat anti-mouse-IgG conjugated to
Alexa Fluor 680 (Invitrogen, RRDI AB_2535723) and goat anti-rabbit-IgG
conjugated to Dylight 800 (Invitrogen, RRDI AB_2556616) secondary
antibodies were used at 1:25,000.
Cell culture conditions
The HeLa cells used in this study were originally sourced from the American
Type Culture Collection. The H1975 and H1299 NSCLC cell lines were
kind gifts from Dr Emma Vincent (School of Cellular and Molecular
Medicine, University of Bristol). We did not independently authenticate the
cell lines. All cell lines were maintained at 37°C with 5% CO2 atmosphere.
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 4.5 g/l glucose (D5796; Sigma-Aldrich), supplemented with
10% (v/v) fetal bovine serum (FBS). H1975 and H1299 cells were
maintained in RPMI 1640 medium (R0883; Sigma-Aldrich), supplemented
with 10% (v/v) FBS and 2 mM L-glutamine. For copper supplement
experiments, cells were incubated for the indicated time at 37°C in medium
containing CuCl2 (Sigma-Aldrich).
Fig. 7. Retromer-deficient cells show reduced sensitivity to the platinum-based drug cisplatin. (A) Control and VPS35 KO HeLa cells were incubated
with nine concentrations of cisplatin (from 0.39 μM to 100 μM) for 48 h and MTT reduction was measured by absorbance at 595 nm. Each data point represents
the mean±s.e.m. absorbance at 595 nm normalised to the baseline reading without addition of cisplatin; n=3 independent experiments. (B) CTR1 cell
surface levels were assessed by surface biotinylation in VPS35 KO H1975 cells. Cells were surface biotinylated and streptavidin–agarose used to capture
biotinylated membrane proteins. The surface abundance of CTR1, ATP7A and the loading controls N-cadherin and transferrin receptor (TfR) were examined by
immunoblotting. The quantification shows the mean±s.e.m.; n=3 independent experiments. (C) Control and VPS35 KO H1975 cells were incubated with nine
concentrations of cisplatin (from 0.39 μM to 100 μM) for 48 h and MTT reduction was measure as described above; n=4 independent experiments.
*P<0.05; **P<0.01 (unpaired Student’s t-test).
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Transfections
DNA was transiently transfected into cells using FuGENE 6 transfection
reagent (Promega), according to the manufacturer’s instructions. The
gRNAs for CRISPR genome editing were cloned into the CRISPR-Cas9
plasmid px330. The gRNAs used in this study were VPS35, 5′-GTGGT-
GTGCAACATCCCTTG-3′ and SNX27, 5′-GGCTACGGCTTCAACGT-
GCG-3′. CRISPR-Cas9 plasmids were co-transfected with a puromycin
resistance-expressing plasmid, and cells were subjected to puromycin
selection 24 h later.
For siRNA-based knockdown, cells were reverse-transfected using
DharmaFECT 1 (GE Healthcare) and then transfected again 24 h later
according to the manufacturer’s instructions. At 48 h after the second
transfection, cells were lysed or fixed and processed for immunofluorescence.
For VPS35 suppression, a combination of oligonucleotides 3 (sequence 5′-
GUUGUUAUGUGCUUAGUA-3′) and 4 (sequence 5′-AAAUACCACU-
UGACACUUA-3′) of the Dharmacon ON-TARGETplus VPS35 siRNA
SMARTpool was used. For SNX27 suppression, Dharmacon ON-
TARGETplus SNX27 siRNA SMARTpool (cat. #L-017346-01) was used.
The non-target control siRNA used was Dharmacon ON-TARGETplus non-
targeting siRNA no. 2 (cat. #D-001810-02).
Quantitative western blot analysis
For western blotting, cells were lysed in PBS containing 2% Triton X-100
and Pierce protease and phosphatase inhibitor tablets (Thermo Fisher
Scientific). The protein concentration was determined with a BCA assay kit
(Thermo Fisher Scientific), and equal amounts were resolved on NuPAGE
4–12% precast gels (Invitrogen). Proteins were transferred from gels onto
PVDF membrane (Immobilon-FL, pore size 0.45 μm, Millipore, catalogue
number IPFL00010) for immunoblotting. Transfer was performed in
transfer buffer (25 mM Tris, 192 mM glycine and 10% methanol) at 100 V
for 70 min. Membranes were blocked in 5% milk in PBS containing 0.1%
Tween 20 (PBS-T) prior to incubation with the appropriate primary
antibodies and fluorescently labelled secondary antibodies. Detection and
quantification were carried out using an Odyssey infrared scanning system
(LI-COR Biosciences).
Cell surface biotinylation
Cells were surface biotinylated 72 h post siRNA transfection or after the
indicated treatment with membrane-impermeable biotin (Thermo Fisher
Scientific) at 4°C to prevent endocytosis. Post-biotinylation, cells were lysed
in PBS containing 2% Triton X-100 and Pierce protease and phosphatase
inhibitor EDTA-free tablets, pH 7.5 and lysates were cleared by
centrifugation. Equal amounts of protein from the control, indicated
knockdown, knockout or treatment lysate were then added to streptavidin–
Sepharose beads to capture biotinylated proteins. Streptavidin beads and
lysates were incubated for 30 min at 4°C before washing in PBS containing
1.2 MNaCl and 1%Triton X-100. Proteins were eluted in 2×NuPAGELDS
Sample Buffer (Life Technologies) by boiling at 95°C for 10 min, then
separated by SDS-PAGE and subjected to quantitative western blot analysis
(as described above).
Immunofluorescence
Cells were washed three times in PBS, fixed in 4% paraformaldehyde (PFA)
and then washed in PBS and permeabilized with 0.1% Triton X-100 or
Fig. 8. Model of retromer-dependent and SNX27–
retromer-dependent plasma membrane recycling of
CTR1 and ATP7A, respectively. In response to
elevated copper or exposure to platinum-based drugs,
such as cisplatin, CTR1 is endocytosed from the plasma
membrane and sequestered on retromer-positive
endosomes. In prolonged high copper or cisplatin
conditions, CTR1 remains associated with the maturing
endosome. Elevated copper in the cell upregulates
SNX27–retromer-dependent ATP7A trafficking from
endosomes to the plasma membrane and/or to the TGN
for re-secretion to expel excess copper. Upon removal of
extracellular copper or cisplatin, CTR1 is recycled back to
the plasma membrane in a retromer-dependent manner
and ATP7A trafficking between the TGN and plasma
membrane is returned to constitutive levels.
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saponin. Fixed cells were then blocked in PBS containing 1% BSA and
incubated with primary antibodies and appropriate secondary antibodies
(Alexa Fluor; Thermo Fisher Scientific) in PBS containing 0.1% BSA.
PBS-washed coverslips were mounted onto glass slides with Mowiol
(Sigma-Aldrich).
Antibody uptake assays
For the CTR1 trafficking assays, cells were seeded onto sterile coverslips.
The following day, cells were surface labelled by incubation with an
antibody against CTR1 (Abcam, ab129067, 1:100, RRDI AB_11150613)
for 30 min on ice. Cells were then incubated at 37°C in excess copper-
containing medium (200 µM CuCl2) or standard growth medium for either
30 min or 2 h as indicated, at which point, cells were fixed in 4% PFA and
processed for immunofluorescence staining as described above.
Flow cytometry
Cells were washed three times in PBS (without Ca2+ or Mg2+), and then
incubated for 20 min with Accutase to detach cells. Then 200,000
resuspended cells were transferred to 5 ml round-bottom polystyrene
tubes (BD Biosciences). Cells were reconstituted in PBS (without Ca or
Mg), containing 1% BSA and incubated with rabbit monoclonal CTR1
antibody (ab129067) or an isotype control antibody (Biolegend, clone
Poly29108) for 1 h on ice. Cells were washed once in ice-cold PBS (without
Ca or Mg) and incubated for 30 min on ice with Alexa Fluor 647 conjugated
donkey anti-rabbit-IgG secondary antibody (Invitrogen, A31573) in PBS
(without Ca2+ or Mg2+), containing 5% BSA. The cells were washed again
and resuspended in PBS (without Ca2+ or Mg2+) containing 1% BSA and
propidium iodide. Fluorescence signals were measured using a FACS
CantoII-F60 machine (BD Biosciences, Oxford, UK). Data were analysed
using Flowjo 7.2.5 software (Flowjo, Ashland, OR).
MTT assay
Cells were seeded into 96-well plates at a density of 8×103 cells/well in
DMEM without Phenol Red supplemented with 10% (v/v) FBS. The
following day, cells were treated with serial dilutions of copper (CuCl2
3.125 µm to 800 µm) or cisplatin (0.39 μM to 100 μM). Each condition and
an untreated control were performed in quadruplicate. After incubation at
37°C with 5% CO2 atmosphere for either 48 or 72 h, as indicated, 20 μl
5 mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; Life Technologies M6496] was added to each well, and the
plates were incubated for an additional 3.5 h at 37°C.MTTwas removed and
150 μl DMSO was added to each well and mixed thoroughly by pipetting.
MTT absorbance was read at 595 nm using a microplate reader. The average
of the quadruplicate reading for each condition was expressed as percentage
of the untreated control.
Image acquisition and analysis
Microscopy images were collected with a confocal laser-scanning
microscope (SP5 AOBS; Leica Microsystems) attached to an inverted
epifluorescence microscope (DMI6000; Thermo Fisher Scientific). A
63×1.4 NA oil immersion objective (Plan Apochromat BL; Leica
Biosystems) and the standard SP5 system acquisition software and
detector were used. Images were captured using Application Suite AF
software (version 2.7.3.9723; Leica Microsystems) and then analysed with
Volocity 6.3 software (PerkinElmer). For colocalization studies, Pearson’s
correlation (measuring the correlation in the variation between two
channels) was measured using Volocity 6.3 software (PerkinElmer).
Statistical analysis
All statistical analyses were performed using Prism 7 (GraphPad
Software). For comparing two groups, statistical analysis was performed
with a Student’s t-test (unpaired, two-tailed). For multiple comparisons,
one-way ANOVAs followed by Dunnett’s multiple comparison test were
used. Data distribution was assumed to be normal, but this was not
formally tested. All quantified western blot and confocal colocalization
data are the mean of at least three independent experiments. Graphs
represent means and s.e.m.
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